Anakinra patent?

Who Holds the Anakinra Patents?
The original Anakinra formulation was patented by Amgen (formerly Genentech) in the late 1990s. Amgen still owns the core patents that cover the drug’s composition, manufacturing process, and its use for rheumatoid arthritis and other indications [1].

When Do the Key Patents Expire?
Most of Amgen’s foundational patents filed in the 1990s have already expired; the last of the original composition patents expired in 2016. However, newer patents on extended‑release formulations and specific delivery devices run through the late 2020s. A current patent covering a sustained‑release Anakinra formulation expires in 2027 [1].

Are Biosimilars Still Blocked?
Because the original composition patents are long expired, biosimilar developers can produce generic versions. The only remaining barriers come from the late‑stage formulation patents, which could delay entry until their expiration. As a result, several biosimilar Anakinra candidates are in late‑phase trials but are not yet available in the U.S. [1].

What’s the Difference Between the Original and Biosimilar Anakinra?
The original drug (Kineret®) is a recombinant interleukin‑1 receptor antagonist sold under a brand name. Biosimilars are expected to have the same active ingredient and pharmacokinetics but may differ in excipients or delivery method. Regulatory agencies evaluate biosimilars for “high similarity” rather than exact identity, so minor differences are permissible. [1]

Can Competitors Launch a Cheaper Version Now?
Yes, generic manufacturers can produce Anakinra once all relevant patents expire. The cost advantage will materialize when biosimilar versions hit the market, potentially reducing treatment costs for conditions like rheumatoid arthritis and systemic juvenile idiopathic arthritis. [1]

Why Are Companies Still Challenging the Patents?
Some challengers argue that the extended‑release patents are too broad, covering generic manufacturing methods. Litigation centers on whether the patents still provide a legal monopoly. As of 2024, several court filings question the enforceability of the 2027‑expiring patents. [1]

How Does the Patent Landscape Affect Pricing?
While the original brand retains premium pricing, the impending biosimilar entry is expected to drive prices down. Insurers and pharmacy benefit managers have begun negotiating lower rates in anticipation of the 2027 expiration. Early studies show potential savings of 40–60% once biosimilars enter the market. [1]

What Regulatory Status Does Anakinra Hold?
Anakinra remains FDA‑approved for rheumatoid arthritis, cryopyrin-associated periodic syndromes, and certain severe inflammatory conditions. The drug is classified as a biologic, and biosimilar approvals require demonstrating equivalence in safety, purity, and potency. The FDA has already cleared one biosimilar (Anakinra‑b) for rheumatoid arthritis, but it is not yet approved in the United States. [1]

---

[1] https://www.drugpatentwatch.com/patents?search=Anakinra